FIGURE 2.

(A) Univariable Kaplan Meier analysis, (B) predicted survival functions based on the final multivariable Cox proportional hazards model for hypothetical patients receiving sorafenib and nivolumab treatments with all covariates set at the mean values, and (C) predicted survival functions based on the Cox proportional hazards model with Inverse Probability of Treatment Weighting (IPTW) for a hypothetical group of patients receiving sorafenib and nivolumab treatments. Predicted survival functions in panels (B) and (C) are for hypothetical groups of patients; thus, the number at risk cannot be calculated.